Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Virpax Reveals Results From A Beagle Dog Dose Range Finding Study; All The Dogs In DRF Study Demonstrated Positive Tolerance To Probudur And No Adverse Effects Were Noted

Author: Benzinga Newsdesk | March 18, 2025 04:03pm

Probudur is the company's long-acting liposomal bupivacaine formulation injected at a wound site to provide both immediate and extended pain relief.

The Company continues to work towards its Investigational New Drug (IND) application and this was another important step towards that milestone.

 

Posted In: VRPX

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist